Helius Medical Technologies(US:HSDT)2025-11-18 22:32Financial Data and Key Metrics Changes - The third quarter revenue was $697,000, which included first-time staking rewards income of $342,000, marking a significant increase from the prior year period [25] - Cost of revenue decreased to $103,000 from $187,000 in the prior year, primarily due to reduced inventory reserve and production scrap expenses [25] - Total operating expenses for the third quarter were $36 million, compared to $3.9 million in the third quarter of 2024, resulting in a loss from operations of $35.4 million, up from a loss of $4.1 million in the prior year [26] - The net loss for the third quarter was $352.8 million, or a loss of $32.89 per share, compared to a net loss of $3.7 million in the prior year [27][28] Business Line Data and Key Metrics Changes - The company has increased its holdings of SOL by approximately $100,000 in the first month of operation, totaling over 2.3 million tokens [15] - The average gross staking yield for October was 7.03% APY, outperforming the stake-weighted average of the top 10 largest validators [16] Market Data and Key Metrics Changes - Trading volume in HSDC has significantly outperformed the average of peer DATs, indicating growing awareness of Solana's fundamentals [10] - The company has been actively engaging with the Asian market, which is seen as a significant under-penetrated area with high potential for Solana [9] Company Strategy and Development Direction - The company aims to build the "Berkshire Hathaway of the Solana ecosystem," focusing on compounding shareholder value and maintaining a strong balance sheet [11] - The digital asset treasury strategy is centered around three pillars: advocacy, capital markets, and treasury management [5][6] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the digital asset treasury market has cooled after a period of rapid expansion, entering an execution and consolidation phase [14] - The company believes it has the necessary ingredients for long-term success, including balance sheet strength and institutional sponsorship [15] Other Important Information - The company successfully raised over $500 million to fund its digital asset treasury strategy in September [4] - The PoNS device submission for FDA 510(k) designation has been filed, reflecting positive clinical outcomes from the stroke registration program [22][23] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with closing remarks from management [29][30]